SG11201804811WA - Fenfluramine compositions and methods of preparing the same - Google Patents

Fenfluramine compositions and methods of preparing the same

Info

Publication number
SG11201804811WA
SG11201804811WA SG11201804811WA SG11201804811WA SG11201804811WA SG 11201804811W A SG11201804811W A SG 11201804811WA SG 11201804811W A SG11201804811W A SG 11201804811WA SG 11201804811W A SG11201804811W A SG 11201804811WA SG 11201804811W A SG11201804811W A SG 11201804811WA
Authority
SG
Singapore
Prior art keywords
international
trifluoromethyl
phenyl
composition
fenfluramine
Prior art date
Application number
SG11201804811WA
Inventor
Derek Londesbrough
Marc W Andersen
Original Assignee
Zogenix International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59065032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201804811W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zogenix International Ltd filed Critical Zogenix International Ltd
Publication of SG11201804811WA publication Critical patent/SG11201804811WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/24—Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds
    • C07C209/28—Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds by reduction with other reducing agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82—Purification; Separation; Stabilisation; Use of additives
    • C07C209/84—Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/72—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78—Separation; Purification; Stabilisation; Use of additives
    • C07C45/80—Separation; Purification; Stabilisation; Use of additives by liquid-liquid treatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/227—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
    • C07C49/233—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/08—Preparation of carboxylic acids or their salts, halides or anhydrides from nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau ristsplid (43) International Publication Date .... ......r el 29 June 2017(29.06.2017) WIPO I PCT ID Hit (10) WO 111111111111111111IIIIIIII International II III 2017/112702 III IIIII Publication 111111111111 IIII Number Al RIO IIII IIIIIIII (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every B01J 23/72 (2006.01) B01J 27/25 (2006.01) kind of national protection available): AE, AG, AL, AM, B01J 27/055 (2006.01) CO7C 45/54 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BOM 27/122 (2006.01) CO7C 49/223 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/US2016/067856 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 20 December 2016 (20.12.2016) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/271,172 22 December 2015 (22.12.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: ZOGENIX INTERNATIONAL LIMITED TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [GB/GB]; Siena Court Broadway, Maidenhead Berkshire TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, SL6 1NJ (GB). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors; and LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (71) Applicants : LONDESBROUGH, Derek [GB/GB]; c/o SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Zogenix International Limited, Siena Court Broadway, GW, KM, ML, MR, NE, SN, TD, TG). Maidenhead Berkshire SL6 1NJ (GB). ANDERSEN, Published: Marc W. 4500 Touchstone Forest Road, [US/US]; 21(3)) Raleigh, North Carolina 27612 (US). — with international search report (Art (74) Agent: FOULDS, Glenn J.; Bozicevic Field & Francis LLP, 201 Redwood Shores Parkway, Suite 200, Redwood City, California 94605 (US). Title: FENFLURAMINE AND METHODS PREPARING THE SAME (54) COMPOSITIONS OF 0 F OH Me 0 Me 0 Acetic Anhydride H 2 N Me Add (4) Ethy amine F 3 C le i 1-1 .4t ei O t--- ei 1-1 1-1 ---- (57) : Methods of preparing a fenfluramine active L 3 / 4 -- (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile :::j position; (b) reacting the 2- (3-(trifluoromethyl)phenyl)acetic ei (3-(trifluoromethyl)phenyl)propan-2-one composition; and 0 composition with ethylamine using a borohydride reducing itions and pharmaceutical ingredients prepared according to fluramine and having less than 0.2% by weight in total of trifluoromethyl (c) FIG. pharmaceutical composition agent the (1 ) 1 ingredient are provided. Aspects of the method include to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid com- acid composition with acetic anhydride and a catalyst to produce a 1- reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one to produce a fenfluramine composition. Also provided are compos- subject methods including a pharmaceutically acceptable salt of fen- regioisomers.
SG11201804811WA 2015-12-22 2016-12-20 Fenfluramine compositions and methods of preparing the same SG11201804811WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562271172P 2015-12-22 2015-12-22
PCT/US2016/067856 WO2017112702A1 (en) 2015-12-22 2016-12-20 Fenfluramine compositions and methods of preparing the same

Publications (1)

Publication Number Publication Date
SG11201804811WA true SG11201804811WA (en) 2018-07-30

Family

ID=59065032

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202005916QA SG10202005916QA (en) 2015-12-22 2016-12-20 Fenfluramine compositions and methods of preparing the same
SG11201804811WA SG11201804811WA (en) 2015-12-22 2016-12-20 Fenfluramine compositions and methods of preparing the same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202005916QA SG10202005916QA (en) 2015-12-22 2016-12-20 Fenfluramine compositions and methods of preparing the same

Country Status (24)

Country Link
US (4) US10351509B2 (en)
EP (3) EP3800177A1 (en)
JP (3) JP6893213B2 (en)
KR (1) KR20180091924A (en)
CN (2) CN108883399B (en)
AU (3) AU2016379346B2 (en)
BR (1) BR112018011777A2 (en)
CA (1) CA3007286A1 (en)
DK (1) DK3393655T3 (en)
ES (1) ES2861774T3 (en)
HR (1) HRP20210267T1 (en)
HU (1) HUE053114T2 (en)
IL (3) IL286391B (en)
LT (1) LT3393655T (en)
MX (1) MX2021000482A (en)
PL (1) PL3393655T3 (en)
PT (1) PT3393655T (en)
RS (1) RS61506B1 (en)
RU (2) RU2731179C2 (en)
SA (1) SA518391868B1 (en)
SG (2) SG10202005916QA (en)
SI (1) SI3393655T1 (en)
WO (1) WO2017112702A1 (en)
ZA (1) ZA201803583B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
BR112018011777A2 (en) * 2015-12-22 2018-12-04 Zogenix International Ltd fenfluramine compositions and methods for preparing them
CA3007673A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
JP2019526544A (en) 2016-08-24 2019-09-19 ゾゲニクス インターナショナル リミテッド Formulations for inhibiting the formation of 5-HT2B agonists and methods of use thereof
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019067413A1 (en) 2017-09-26 2019-04-04 Zogenix International Limited Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
EP3883555A1 (en) 2018-11-19 2021-09-29 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
EP3887481A4 (en) * 2018-11-30 2022-08-03 Zogenix International Limited A method of treating refractory epilepsy syndromes using fenfluramine enantiomers
CN114585354A (en) 2019-09-17 2022-06-03 周格尼克斯国际有限公司 Method for treating epileptic patients with fenfluramine
WO2021117057A1 (en) * 2019-12-10 2021-06-17 Maithri Drugs Pvt Ltd Polymorph of n-ethyl-1-(3-(trifluoromethyl)phenyl)propan-2-amine hydrochloride and process for preparation thereof
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2023037182A2 (en) * 2021-08-19 2023-03-16 Biophore India Pharmaceuticals Pvt Ltd AN IMPROVED PROCESS FOR THE PREPARATION OF N-ETHYL- α -METHYL-3-(TRIFLUOROMETHYL)PHENETHYLAMINE HYDROCHLORIDE

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR104F (en) * 1960-11-05
US3117160A (en) 1961-07-27 1964-01-07 Pfizer & Co C Aralkylamines
US3198834A (en) 1964-07-27 1965-08-03 Snc Science Union Et Compagnie Optical isomers of trifluoromethylated phenethylamines
GB1254332A (en) 1969-02-27 1971-11-17 Science Union & Cie Amino acids and their derivatives and processes for preparing them
DE2143204C3 (en) 1971-08-28 1979-09-27 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt N-fluoroalkyl-phenylisopropylamine derivatives and their salts, processes for their preparation and pharmaceuticals based on them
DE2150399A1 (en) 1971-10-09 1973-04-12 Hoechst Ag Alpha-oximinobenzyl cyanides - useful as pesticide inters
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
JPS54144347A (en) * 1978-05-02 1979-11-10 Nikken Kagaku Kk 3-(2-fluoro-4-biphenylyl)-2-butanone
US4452815A (en) 1980-06-16 1984-06-05 Massachusetts Institute Of Technology Method of utilizing d,l-fenfluramine for modifying feeding behavior
US4309445A (en) 1980-06-16 1982-01-05 Massachusetts Institute Of Technology d-Fenfluramine for modifying feeding behavior
US4721823A (en) * 1986-09-19 1988-01-26 Pennzoil Products Company Lubricants comprising novel cyclopentanes, cyclopentadienes, cyclopentenes, and mixtures thereof and methods of manufacture
DE3717434C1 (en) * 1987-05-23 1988-09-15 Degussa Process for the preparation of m-trifluoromethylphenylacetonitrile
KR890003368A (en) * 1987-08-06 1989-04-14 원본미기재 How to treat nausea and vomiting with certain substituted phenylalkylamino (and amino acid) derivatives and other serotonin-lowering agents
US4857533A (en) 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
HU204497B (en) 1989-10-09 1992-01-28 Chinoin Gyogyszer Es Vegyeszet Process for producing phenfluramine
IT1238686B (en) * 1990-02-09 1993-09-01 Lab Mag Spa PROCEDURE FOR THE PREPARATION OF LEVO AND RIGHT FENFLURAMINA
FR2684552B1 (en) 1991-12-06 1995-04-28 Adir USE OF D-FENFLURAMINE AND FENFLURAMINE DERIVATIVES IN THE TREATMENT OF HYPERTENSION IN INSULIN RESISTANT SUBJECTS.
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5708018A (en) 1993-08-06 1998-01-13 Pharmacia & Upjohn Company 2-aminoindans as selective dopamine D3 ligands
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5412102A (en) 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
CA2191996A1 (en) * 1994-06-03 1995-12-14 Thejmde Trust Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof
IT1298349B1 (en) * 1996-05-29 2000-01-05 Alfa Chem Ital PROCESS FOR THE PRODUCTION OF 1 - (3-TRIFLUOROMETHYL) PHENYL-PROPAN- 2-ONE INTERMEDIATE IN THE SYNTHESIS OF PHENFLURAMINE
IT1292885B1 (en) * 1997-04-28 1999-02-11 Alfa Chem Ital PROCESS FOR THE PRODUCTION OF (R) AND (S) - ALPHA-METHYL-3- (TRIFLUOROMETHYL) BENZENE-ETHANAMINE ISOMERS.
EP0920864A1 (en) 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
US20020098175A1 (en) 1998-06-16 2002-07-25 Zohoungbogbo Mathias C. Dietetic food composition and dietetic method using such composition
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
AU779354B2 (en) 1998-12-23 2005-01-20 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7124031B1 (en) 2000-05-11 2006-10-17 Medco Health Solutions, Inc. System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
US20020038310A1 (en) 2000-07-17 2002-03-28 Reitberg Donald P. Single-patient drug trials used with accumulated database: genomic markers
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
JP2005503425A (en) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション Delivery of drug ester by the prescribed inhalation route
US7585493B2 (en) * 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
ES2339339T3 (en) 2001-06-22 2010-05-19 Universite Catholique De Louvain PEARLS OR HYDROGEL CAPSULES AS ARTIFICIAL MEANS FOR INSPECTION OVIPOSITION AND ENDOPARASITOID BREEDING.
CA2455939C (en) 2001-07-31 2011-03-22 Wyeth Llc Sucralose formulations to mask unpleasant tastes
AUPR732601A0 (en) * 2001-08-28 2001-09-20 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of amines such as ephedrine and inter mediates
RU2317104C2 (en) * 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Method for modifying alimentary behavior and application of pyy or its agonist as a preparation for modifying alimentary behavior
EP2050460A1 (en) 2001-09-24 2009-04-22 Imperial Innovations Limited PYY and agonists thereof for modification of feeding behaviour
US6599901B1 (en) 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
CA2478183C (en) 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
WO2003082191A2 (en) 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
WO2005004865A1 (en) 2003-07-08 2005-01-20 Georg-August-Universität Göttingen Use of 5-ht4(a)-serotonin receptor agonists
GB0410266D0 (en) 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
US20050260610A1 (en) 2004-05-20 2005-11-24 Kurtz Richard E Method for diagnosing and prescribing a regimen of therapy for human health risk
US9820658B2 (en) 2006-06-30 2017-11-21 Bao Q. Tran Systems and methods for providing interoperability among healthcare devices
CA2602899A1 (en) 2005-03-21 2006-09-28 Software Solutions Limited System for continuous blood pressure monitoring
RU2007148444A (en) 2005-05-25 2009-06-27 Янссен Фармацевтика Н.В. (Be) PEDIATRIC TOPIRAMAT COMPOSITION
NZ564892A (en) 2005-06-16 2011-10-28 Bionomics Ltd Methods of treatment, and diagnosis of epilepsy by detecting a D674G mutation in the SCN1A gene
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
WO2007031846A2 (en) 2005-09-14 2007-03-22 University Of The Witwatersrand, Johannesburg Pharmaceutical composition
US8109891B2 (en) 2005-09-19 2012-02-07 Biolert Ltd Device and method for detecting an epileptic event
EP1958111A4 (en) 2005-11-29 2009-07-08 Childrens Hosp Medical Center Optimization and individualization of medication selection and dosing
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007079181A2 (en) 2005-12-28 2007-07-12 Neurovista Corporation Methods and systems for recommending an action to a patient for managing epilepsy and other neurological disorders
EP1988885A2 (en) 2006-02-06 2008-11-12 Novartis AG Combination of organic compounds
WO2008068625A2 (en) 2006-06-08 2008-06-12 Medichem, S.A. Processes for preparing cinacalcet hydrochloride and polymorphic forms thereof
DE102006030113B4 (en) 2006-06-28 2009-02-12 Chemische Fabrik Budenheim Kg Graphite-free high-temperature lubricant
WO2008025148A1 (en) 2006-08-31 2008-03-06 The Governors Of The University Of Alberta Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators
WO2008095095A2 (en) 2007-01-31 2008-08-07 Quintiles Transnational Corp. Methods and systems for allocating representatives to sites in clinical trials
ES2599227T3 (en) 2007-02-08 2017-01-31 Biogen Ma Inc. Neuroprotection in demyelinating diseases
JP2010520162A (en) * 2007-02-28 2010-06-10 スミスクライン ビーチャム コーポレーション Thiadiazole derivatives that are stearoyl-CoA desaturase inhibitors
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
WO2010015029A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
WO2010020585A1 (en) 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
PT2331210E (en) 2008-09-05 2014-08-25 Gruenenthal Gmbh Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an antiepileptic
US8664442B2 (en) 2008-09-09 2014-03-04 Chemtura Corporation Anti-oxidants
US8386274B1 (en) 2008-09-17 2013-02-26 Mckesson Financial Holdings Limited Systems and methods for a prescription safety network utilizing eligibility verification transactions
GEP20135723B (en) 2008-10-09 2013-01-10 Acraf Liquid pharmaceutical composition containing paracetamol
CA2776945A1 (en) 2008-10-10 2010-04-15 The United States Of America, As Represented By The Secretary Of The Arm Y, On Behalf Of Walter Reed Army Institute Of Research Methods and compositions for treating status epilepticus and seizures causing status epilepticus
TWI424832B (en) 2008-12-15 2014-02-01 Proteus Digital Health Inc Body-associated receiver and method
EP2406765A4 (en) 2009-03-09 2014-12-31 Celgene Corp Device for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated and methods for use thereof
AU2010236404B2 (en) 2009-04-15 2016-11-03 Research Triangle Institute Monoamine reuptake inhibitors
WO2010124137A1 (en) 2009-04-22 2010-10-28 Millennium Pharmacy Systems, Inc. Pharmacy management and administration with bedside real-time medical event data collection
US9453027B2 (en) 2009-07-27 2016-09-27 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
TW201127375A (en) 2010-01-08 2011-08-16 Eurand Inc Taste masked topiramate composition and an orally disintegrating tablet comprising the same
EP3255574A1 (en) 2010-03-09 2017-12-13 Perceptimed, Inc. Medication verification and dispensing
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
JP2011221623A (en) 2010-04-06 2011-11-04 Kakimori Suri Home medical care support system and method
EP2571858B1 (en) 2010-05-21 2018-06-20 Research Triangle Institute Phenylmorpholines and analogues thereof
EP2399513B1 (en) 2010-06-23 2017-01-04 Qatar University Qstp-B System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms
CN103108651A (en) 2010-07-30 2013-05-15 默沙东公司 Inhibition of cyp3a drug metabolism
EP3485878A1 (en) 2010-09-01 2019-05-22 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-ht2c agonists useful for weight management
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
KR20160017668A (en) 2010-10-26 2016-02-16 알파마 파머슈티컬스 엘엘씨 Formulations and methods for attenuating respiratory depression induced by opioid overdose
RU103209U1 (en) 2010-10-29 2011-03-27 Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" CLINICAL INFORMATION SYSTEM
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
JP5693325B2 (en) 2011-03-29 2015-04-01 小林クリエイト株式会社 Medical examination result output system and medical examination result output program
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
WO2013096878A1 (en) 2011-12-22 2013-06-27 University Of Idaho Garcinia buchananii baker compounds, compositions and related methods
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US20130218586A1 (en) 2012-02-21 2013-08-22 Frederic J. Huser Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status
JP6075973B2 (en) 2012-06-04 2017-02-08 富士通株式会社 HEALTH STATE JUDGING DEVICE AND ITS OPERATION METHOD
EP2920155A2 (en) 2012-11-15 2015-09-23 Galleon Pharmaceuticals, Inc. Novel orally bioavailable breathing control modulating compounds, and methods of using same
WO2014106825A2 (en) 2013-01-06 2014-07-10 Jonathan Rabinowitz Methods and devices for identifying improper medical reporting
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103342648A (en) 2013-07-22 2013-10-09 北京科莱博医药开发有限责任公司 Method for preparing retigabine intermediate and method for preparing retigabine
LT3035926T (en) 2013-08-19 2020-11-25 The Regents Of The University Of California Compounds and methods for treating an epileptic disorder
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2015077057A1 (en) 2013-11-20 2015-05-28 Texas Southern University Methionine aminopeptidase inhibitors for treating infectious diseases
CN103886415A (en) 2014-03-25 2014-06-25 北京蝶禾谊安信息技术有限公司 Method and device for managing drugs
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
JP6466116B2 (en) 2014-09-12 2019-02-06 株式会社東芝 Operation control system
MX2017004065A (en) 2014-09-29 2017-07-24 Zogenix Int Ltd Control system for control of distribution of medication.
IL252848B1 (en) 2015-02-06 2024-03-01 Marinus Pharmaceuticals Inc Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
WO2016138138A1 (en) 2015-02-25 2016-09-01 The Regents Of The University Of California 5ht agonists for treating disorders
US10292996B2 (en) 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
JP6668045B2 (en) 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド Selective 5-HT receptor agonists and antagonists for treating Dravet syndrome
RS60572B1 (en) 2015-06-17 2020-08-31 Univ Columbia Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes
NO346258B1 (en) 2015-06-30 2022-05-16 Neurad Ltd Novel breathing control modulating compounds, and methods of making and using same
US10004749B2 (en) 2015-07-22 2018-06-26 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
WO2017035267A1 (en) 2015-08-24 2017-03-02 Zogenix International Limited Methods of treating lennox-gastaut syndrome using fenfluramine
US20220193082A1 (en) 2015-09-14 2022-06-23 Zogenix International Limited Combination treatment of specific forms of epilepsy
US20170071949A1 (en) 2015-09-14 2017-03-16 Zogenix International Limited Combination treatment of specific forms of epilepsy
EP3170807B1 (en) 2015-11-23 2019-12-11 Frau Pharma S.r.l. New method for synthesis of fenfluramine
CA3007673A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
BR112018011777A2 (en) 2015-12-22 2018-12-04 Zogenix International Ltd fenfluramine compositions and methods for preparing them
CN108699312B (en) 2016-01-14 2021-04-20 Ａｇｃ株式会社 Fluororesin solution, method for producing fluororesin solution, coating composition, and coated article
JP2019526544A (en) 2016-08-24 2019-09-19 ゾゲニクス インターナショナル リミテッド Formulations for inhibiting the formation of 5-HT2B agonists and methods of use thereof
US20190083425A1 (en) 2016-08-24 2019-03-21 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
US20180092864A1 (en) 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
EP3634392A1 (en) 2017-05-09 2020-04-15 Zogenix International Limited Methods of treating doose syndrome using fenfluramine
US20190125697A1 (en) 2017-09-26 2019-05-02 Zogenix International Limited Method of reduction in convulsive seizure frequency
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
WO2019067413A1 (en) 2017-09-26 2019-04-04 Zogenix International Limited Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US20190247333A1 (en) 2017-09-26 2019-08-15 Zogenix International Limited Method of reduction in convulsive seizure frequency
US11352882B2 (en) 2018-03-12 2022-06-07 Cameron International Corporation Plug assembly for a mineral extraction system
WO2019204593A1 (en) 2018-04-18 2019-10-24 The Trustees Of Columbia University In The City Of New York Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
WO2020014075A1 (en) 2018-07-10 2020-01-16 Zogenix International Limited Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension
CR20210095A (en) 2018-07-27 2021-06-01 Xenon Pharmaceuticals Inc Method for treating epilepsy
EP3883555A1 (en) 2018-11-19 2021-09-29 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
EP3887481A4 (en) 2018-11-30 2022-08-03 Zogenix International Limited A method of treating refractory epilepsy syndromes using fenfluramine enantiomers
US20220133652A1 (en) 2019-02-25 2022-05-05 Zogenix International Limited A formulation for improving seizure control
US20210299064A1 (en) 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20220096514A1 (en) 2020-09-29 2022-03-31 Zogenix International Limited Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine

Also Published As

Publication number Publication date
EP3393655B1 (en) 2020-12-09
PL3393655T3 (en) 2021-09-20
AU2016379346A1 (en) 2018-07-05
AU2021202576A1 (en) 2021-05-27
US10351510B2 (en) 2019-07-16
DK3393655T3 (en) 2021-03-15
EP3393655A4 (en) 2019-07-24
JP2019501173A (en) 2019-01-17
LT3393655T (en) 2021-03-25
RU2018121633A (en) 2020-01-23
US20170174613A1 (en) 2017-06-22
AU2021201339A1 (en) 2021-03-18
JP6893213B2 (en) 2021-06-23
CA3007286A1 (en) 2017-06-29
JP2022133279A (en) 2022-09-13
JP7394919B2 (en) 2023-12-08
SG10202005916QA (en) 2020-07-29
EP3800177A1 (en) 2021-04-07
MX2021000482A (en) 2022-03-29
IL286391B (en) 2022-08-01
IL259703A (en) 2018-07-31
EP3393655A1 (en) 2018-10-31
RU2020128323A3 (en) 2021-01-29
CN108883399A (en) 2018-11-23
US10947183B2 (en) 2021-03-16
RU2731179C2 (en) 2020-08-31
RU2018121633A3 (en) 2020-03-20
SA518391868B1 (en) 2021-09-08
IL281368A (en) 2021-04-29
EP4293009A2 (en) 2023-12-20
US11634377B2 (en) 2023-04-25
US20180148403A1 (en) 2018-05-31
RS61506B1 (en) 2021-03-31
IL286391A (en) 2021-10-31
US20210147335A1 (en) 2021-05-20
AU2016379346B2 (en) 2021-02-18
BR112018011777A2 (en) 2018-12-04
JP2021054831A (en) 2021-04-08
AU2021201339B2 (en) 2021-10-21
AU2021202576B2 (en) 2022-03-03
US10351509B2 (en) 2019-07-16
RU2020128323A (en) 2020-10-06
CN108883399B (en) 2021-06-22
ES2861774T3 (en) 2021-10-06
EP4293009A3 (en) 2024-02-21
WO2017112702A1 (en) 2017-06-29
SI3393655T1 (en) 2021-05-31
JP7412320B2 (en) 2024-01-12
IL259703B (en) 2021-04-29
US20190284124A1 (en) 2019-09-19
IL281368B (en) 2021-10-31
CN113499330A (en) 2021-10-15
KR20180091924A (en) 2018-08-16
PT3393655T (en) 2021-02-23
HUE053114T2 (en) 2021-06-28
HRP20210267T1 (en) 2021-05-14
ZA201803583B (en) 2019-03-27

Similar Documents

Publication Publication Date Title
SG11201804811WA (en) Fenfluramine compositions and methods of preparing the same
SG11201907023UA (en) Method of reducing neutropenia
SG11201803686UA (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
SG11201909325RA (en) 2-amino-quinoline derivatives
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201806745RA (en) Sulfonylureas and related compounds and use of same
SG11201811150WA (en) Ev-mediated delivery of binding protein-small molecule conjugates
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201908604YA (en) Fused imidazo-piperidine jak inhibitor compound
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201908420WA (en) Compositions of plinabulin and use thereof
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201408261UA (en) Syringe
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201810872UA (en) Composition and method for reducing neutropenia
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto